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Abstract: The aim of this study was to investigate the influence of oral iron supplementation, in the
form of fortified breads, on the growth performance, health, iron status parameters, and fecal
metabolome of anemic piglets. A study was conducted on 24 hybrid (Large White × Landrace
× Duroc) piglets. From day 44, the post-natal 12 piglets were supplemented with 100 g of one of
two experimental breads, each fortified with 21 mg of ferrous sulphate, either encapsulated or not.
After one week of oral supplementation, hematological parameters (hematocrit value, hemoglobin,
and red blood cells) showed statistically significant differences (p≤ 0.05). Piglets fed with the fortified
breads had higher iron concentrations in the heart, liver, and intestinal mucosa compared to anemic
piglets fed with control bread. Gene expression of hepcidin, iron exporter ferroportin (IREG1),
and divalent metal transporter 1 (DMT1), together with concentrations of plasma ferritin, showed no
significant statistical differences between groups. Both fortified breads could be used as sources of
bioavailable iron. The seven-day intervention trial showed microencapsulation to have only a mild
effect on the effectiveness of iron supplementation in the form of fortified bread.
Keywords: microencapsulated iron; fortified bread; iron bioavailability; piglet model; iron deficiency;
anemia; metabolome
1. Introduction
Iron is an essential metalloelement for the physiology and biochemistry of most forms of living
organism [1]. Well-nourished people generally have 4 to 5 grams of iron in their bodies, making it the
most abundant trace element in the human body [2,3]. The functional iron pool consists of structural
components in heme proteins—hemoglobin, myoglobin, and cytochrome-dependent proteins [3].
Approximately 2 grams of iron is stored by adult men in proteins such as ferritin and hemosiderin,
and somewhat less by women of childbearing age. Both the functional and stored iron pools are
maintained by the balance between intestinal absorption of dietary iron and iron losses via the
gastrointestinal tract, loss of blood (e.g., menstruation), sweat, skin, or urine [4,5].
The absorption of dietary iron is regulated by physiological factors such as bioactive hepcidin
peptide, iron importer divalent metal transporter 1 (DMT1), and the cellular iron exporter ferroportin
(IREG1) [6]. The molecular target of hepcidin is IREG1, which supplies iron to plasma from duodenal
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enterocytes engaged in dietary iron adsorption, from macrophages of the spleen and liver which recycle
old red blood cells, and from hepatocytes involved in iron storage [7,8]. The interaction of hepcidin and
IREG1 results in the internalization and degradation of the ligand-receptor complex, which decreases
the delivery of iron to plasma. DMT1 is the most important apical uptake transporter of inorganic iron
in enterocytes, which import ferrous iron. DMT1 is essential for normal iron homeostasis [6].
Iron deficiency is the most common nutritional disorder, affecting people of all ages worldwide,
and mammals in general [9,10]. According to the WHO, nutritional iron deficiency affects 1.5–2 billion
people worldwide [11,12]. Iron deficiency is associated with diminished work productivity,
lower immunity, and impaired cognitive development. Iron deficiency can be caused by inadequate
iron intake, compromised bioavailability, and increased iron losses, or a combination of these.
The predominant dietary form of iron is non-heme iron, which accounts for 70%–90% of dietary
iron intake in the world, with higher intake in the developing world than in developed countries [13].
Non-heme iron absorption is in the range of 5%–15%. The two major dietary inhibitors of absorption
are phytates and polyphenols [14]. The most significant enhancer of iron bioavailability is ascorbic
acid, which both reduces and chelates iron, rendering it soluble and available for absorption in the
gut [15].
Iron deficiency can be treated using oral iron supplements, such as ferrous sulfate,
ferrous gluconate, and ferrous fumarate [16]. However, inorganic iron supplements have limitations,
including poor bioavailability and potential adverse effects in the gastrointestinal tract, primarily due
to the oxidative toxicity of ferrous iron [17]. New types of iron supplements with minimal side effects
and dietary sources with high absorption efficiency, such as fortified foods, are therefore needed.
Food fortification is considered the most cost-effective population-based strategy in the long-term to
combat micronutrient malnutrition, effective with no or fewer side effects than supplementation [18].
This study set out to investigate the effects of two experimental breads—each fortified with
ferrous sulphate, either encapsulated or not—on iron status indicators, with piglets used as models.
Iron encapsulation was chosen because of its potential to help overcome unwanted sensory changes in
fortified food, reduce interactions of Fe with food components, and increase Fe bioavailability [19,20].
Swine provide possibly the best preclinical animal model for investigating the gastrointestinal system
and its functions [21,22]. New piglet models are constantly emerging [23]. Iron deficiency is extremely
common in pigs, and is considered to be a para-physiological condition by zootechnical standards.
Indeed, it is mandatory to supplement piglets with exogenous iron within few days of birth, in order
to compensate for poor iron storage by the mothers and the immaturity of the piglets’ absorption
mechanisms [24]. This species is therefore extremely useful for use in preclinical trials concerning iron
deficiency and food supplementation.
2. Material and Methods
2.1. Experimental Breads and Diet of Piglets
The control bread (CB) and iron fortified breads (FeMB and FeSB) were made according to
a procedure developed and optimized at the University of Bologna (UNIBO). The breadmaking
process was based on dried compressed yeast (Lesaffre, San Quirico, Italy). The dough was fermented
for 45 min at a controlled temperature (30 ◦C) and then portioned. The pieces were fermented for
another 45 min under the same conditions, then baked at 195 ◦C for 45 min. All samples were obtained
from the same batch.
The fortified bread was made from an iron fortified mix of white wheat flour (type 650) and
encapsulated ferrous sulphate supplied by EPSA (Valencia, Spain). The experimental breads were
produced in the form of sandwich loafs, sliced, and fresh frozen. Each morning, a small aliquot was
thawed and given to the animals after crumbling.
Analysis of the humidity, fat content, and content of soluble sucrose/saccharose in the breads
was performed according to Polish standard norm ref. no PN-A-74108:1996, Bakery products—testing
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methods. Protein content was calculated based on nitrogen content, determined using the Kjeldahl
method (AOAC 950.36-1950, Protein in bread). The ash residue of the flour was measured using
AOAC Official method 923.03. Total dietary fiber was quantified using an assay kit (Sigma, St. Louis,
MO, USA).
A low iron swine diet (LISD), providing the lowest possible amount of iron, was designed for
the purposes of the experiment. The standard commercial swine feed could not be used as the basal
diet, due to its iron content equivalent to dietary requirements. The LISD was composed of corn flour
(40%), barley flour (10%), barley flakes (20%), soybean flour (20%), and bran (10%). The iron content
.in this diet formula was one tenth of that found in standard commercial swine feed.
2.2. Animals
Twenty-four commercial hybrid (Large White × Landrace × Duroc) piglets, born within the
ASA Unit (DIMEVET, UNIBO), were enrolled in the study. Twelve of the animals were born of one
sow, and the other 12 to two different sows 4 days later. All of the sows were inseminated using
artificial insemination doses from the same boar, in an attempt to standardize the piglets as much
as possible. The animals were monitored daily to assess their clinical condition. All of the activities
performed on the animals were approved by the Local Ethics Committee and the Italian Ministry of
Health (Legislative Decree 116/92, protocol number 10-75-2013).
2.3. Trial Design and Feeding Protocol
Five days after birth (P5), the animals were randomly assigned to four groups (six piglets in
each group, n = 6). Only one of the four groups received regular intramuscular (IM) supplementation
with 1 mL iron dextran (Endofer, Fatro IT, 100 mg·iron·mL−1). Groups are represented in Table 1.
The experiment was divided into two identical blocks to guarantee better management of the animals
and to ensure that they were of the same age at the starting point. During their first 14 days of life,
the piglets were suckled on sow milk only. During the last phase of lactation (P14), LISD was placed in
the mangers of the farrowing crates to accustom the animals to solid feed. The same diet was then left
in quantities sufficient for the piglets to eat ad libitum throughout the rest of the trial.
Table 1. Experimental groups.
Treatments
Piglets Group
FeMB-G1 FeSB-G2 CB-G3 CB-G4
Intramuscular iron






Iron Bread Control Bread Control Bread
In order to start training the piglets to eat the experimental breads, control bread (CB) was added
to the LISD until weaning. After weaning (P28), the piglets were individually fed with 50 g of CB each
day. Starting on day 44 (P44), the animals were individually fed 100 g of either the control or fortified
bread, depending on the experimental group, for 7 days until the end of the trial (P51).
Two groups were fed with iron fortified experimental breads. One group was fed
microencapsulated iron bread (FeMB-G1), the other was fed bread containing the same quantity
of iron sulphate, starch and citric acid (FeSB-G2). The remaining two groups were the control groups.
One (CB-G3) ate control bread, while the other (CB-G4) ate control bread and was given IM iron
supplements from P5.
To guarantee that the piglets ingested the required quantity of bread, it was mixed with water
(100 g of bread, 130 mL−1 water) and fed to the piglets through a 50 mL syringe connected to
a silicon tube, which the animals were given to suck. Vanilla extract was added to improve the flavor.
Nutrients 2017, 9, 272 4 of 15
The weight of individual piglets was monitored periodically (P5, P28, P44, and P51) using a livestock
scale (CO.BA di Melloni Giuseppe e C. SNC, Pieve di Cento IT).
2.4. Sampling Protocol
Blood samples were collected at P5, P44, and P51. Fecal samples were collected from the rectum
at P44 and P51. Urine and tissue samples were collected only at P51, upon euthanasia.
Blood samples were collected under general anesthesia via the femoral artery, using a 21G
butterfly needle and a vacuum system. Tubes with K3EDTA anticoagulant and clot activator were
used (Venosafe®, Terumo, Leuven, Belgium). Samples in K3EDTA for a complete blood count (CBC),
and serum (obtained by 1000 g × 10 min centrifugation) for biochemical profiling, were analyzed by
the Veterinary Clinical Pathology Service of DIMEVET (UNIBO).
At the end of the trial, the animals were sedated by an intramuscular (IM) injection of
Tiletamine-Zolazepam (Zoletil, Virbac, Praga) (5 mg·kg−1). General anesthesia was induced 10 min
later, using an intravenous (IV) bolus of Thiopental sodium (Pentothal, MSD Animal Health s.r.l.)
(10 mg·kg−1). After blood and urine had been collected, the animals were euthanized by an IV bolus
of Tanax (0.3 mL·kg−1, Intervet, Milano, Italy) for extensive sampling.
Immediately after euthanasia, the digestive tract was removed and separated into its anatomical
parts. Mucosal scraping of the stomach wall (lower body part, near pyloric antrum) was performed
using a glass microscope slide, and the mucosa was flash frozen in liquid nitrogen. A 25 cm long
segment of the small intestine (beginning ~10 cm distal to the pyloric sphincter) was removed, cut open
longitudinally, and rinsed with PBS [25]. Duodenal scrapings from the first 10 cm of exposed mucosa
were taken and the tissue was immediately frozen in liquid nitrogen for gene expression analysis.
The second 15 cm of mucosa was scraped and frozen for total iron content analysis. Samples of organs
(liver, heart, spleen, and kidney) were in part conserved for gene expression analysis using RNAlater
(Ambion, ThermoFisher, Waltham, MA, USA) and in part flash frozen in liquid nitrogen for iron
determination. Stomach contents, feces, and urine were collected in sterile tubes, frozen immediately,
and stored at −20 ◦C.
2.5. Hematological Tests
CBC was performed using an automated hematology analyzer (ADVIA 2120, Siemens Healthcare
Diagnostics, Tarrytown, NY, USA). All of the classic hematological variables were analyzed, along with
relatively new platelet and reticulocyte indices.
Biochemical analyses were performed on an automated chemistry analyzer (Olympus AU 400,
Beckman Coulter/Olympus, Brea, CA, USA), including analyses of total iron (TI) and unsaturated iron
binding capacity (UIBC). TI and UIBC, analyzed using a colorimetric method, were used to further
calculate the total iron binding capacity (TIBC) and the TIBC saturation percentage (TSAT).
2.6. Total Iron and Fe(II)
The concentration of iron in wet-digested samples of organs (liver, spleen, heart, and kidney),
whole blood, diets, and feces was determined using atomic absorption spectrophotometry.
The Standard Berghof (Berghof Products + Instruments GmbH Labor Technik, Eningen, Germany)
method for microwave digestion of wheat was applied to the gastric content and whole blood samples.
Briefly, 1 g or 0.5 mL (blood) samples were digested in 10 mL of concentrated nitric acid and 2 mL
hydrogen peroxide using a three-step digestion program, with the temperature raised to 170 ◦C and
a total digestion time of 25 min. For the intestinal mucosa samples, the volume of acid and hydrogen
peroxide was reduced by half. Before digestion, the samples of gastric content were homogenized
using a Glas Col GKH Control Stirrer Mixer.
The digested samples were diluted with deionized water and the iron content was determined by
AAS using a GBC 932 spectrophotometer (GBC Scientific Equipment Pty Ltd., Braeside, Australia),
with a hollow cathode lamp for iron, at 248.3 nm. Acetylene and air flow were fine-tuned daily.
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Standard curves were prepared daily by diluting iron standard reference materials (1000 µg·cm−3;
JT Baker®Chemicals, Phillipsburg, NJ, USA) with deionized water to concentrations of between 0 and
10 µg·cm−3. Certified reference material, whole blood L-1 (Seronorm™ Trace Elements Serum L-1),
was used to test the accuracy of the methods. Iron recovery from whole blood was 97%. During analysis,
precautions were taken to avoid contamination of the iron samples. A ceramic cutter was used.
The glassware was washed in 10% HCl and rinsed three times in ultrapure water.
The presence of Fe(II) was determined through the reaction of formation blue coordinating
compound, formed by chelation of Fe(II) with Ferene S reagent (3-(2-pyridyl)-5,6-difurylsulfonic
acid-1,2,4-triazine sodium salt) under acidic conditions [26].
2.7. RNA Isolation and Quantitative Real Time PCR (qPCR) for HAMP, IREG1, and DMT1
Total RNA was isolated from liver and duodenal mucosa samples using a NucleoSpin®RNA Kit
(Macherey-Nagel GmbH & Co. KG, Düren, Germany). One microgram of total high quality RNA
(A260/A280 ratio above 2.0) was reverse-transcribed in cDNA using an iScript cDNA Synthesis Kit
(Bio-Rad Laboratories Inc., Hercules, CA, USA), with a final volume of 20 µL. Real-time quantitative
PCR was carried out using a CFX 96 Real Time System (Bio-Rad) and iTaq Universal SYBR Green
Supermix (Bio-Rad). All samples were analyzed in duplicate (10 µL/well). The amplification reaction
(20 µL) contained 10 µL of iTaq Universal SYBR Green Supermix, 0.8 µL of each forward and reverse
primer (5 µM), and 2 µL of cDNA. All samples were performed in duplicate. Controls lacking a cDNA
template were included to determine the specificity of target amplification. The real-time program
included an initial denaturation period of 1 min 30 s at 95 ◦C, 40 cycles at 95 ◦C for 15 s, and 60 ◦C
for 30 s, followed by a melting step with ramping from 55 ◦C to 95 ◦C at a rate of 0.5 ◦C/10 s.
The specificity of the amplified PCR products was confirmed by melting curve analysis and agarose
gel electrophoresis. The expression of the hepcidin gene (HAMP, hepcidin antimicrobial peptide) was
evaluated on cDNA derived from liver tissue, while the gene expression of iron transporters (IREG1
and DMT1) was assessed on cDNA derived from duodenum. The swine primer sequences are reported
in Table 2.
The relative expressions of the studied genes were normalized based on the geometric mean
of two reference genes (GAPDH, glyceraldehyde-3-phosphate dehydrogenase and RPL35 ribosomal
protein L35). The relative mRNA expression of the tested genes was evaluated in relation to the control
group (CB-G4) using the 2−∆∆Ct method [27].
Table 2. Primer sequences used for quantitative real-time polymerase chain reaction analysis.










158 XM_003359590.1 Present studyRev: AGGATGACCGAAACATTCTG
DMT1
For: AGGATCTAGGGCATGTGGTG











2.8. Ferritin in Plasma
The specific Pig Ferritin Sandwich ELISA (Cod. LS-F6483, LifeSpan BioScience, Inc., Seattle, WA,
USA) was used for the ferritin assay. Plasma ferritin concentrations were extrapolated from a standard
curve, as described in the manufacturer’s protocol.
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2.9. Metabolomics of Feces
Fecal samples were prepared for proton nuclear magnetic resonance spectroscopy (1H-NMR)
analysis by vortex mixing 80 mg of stool for 5 min with 1 mL of deionized water, followed by
centrifugation, for 15 min at 18,630 g and 4 ◦C. Seven hundred microliters of supernatant was added
to 100 µL of a 10 mM solution of 3-(trimethylsilyl)-propionic-2,2,3,3-d4 acid sodium salt (TSP) in
D2O, buffered at pH 7.00 with 1 M phosphate buffer. Immediately before analysis, the samples were
centrifuged again. 1H-NMR spectra were recorded at 298 K using an AVANCE III spectrometer (Bruker,
Milan, Italy) operating at 600.13 MHz.
The HOD residual signal was suppressed by applying the first increment of the NOESY pulse
sequence and a spoil gradient [30]. The NOESYGPPR1D sequence, part of the standard pulse sequence
library, was used. Each spectrum was acquired by summing up 256 transients using 32 K data
points over 7211.54 Hz (for an acquisition time of 2.27 s). To apply NMR as a quantitative technique,
the recycle delay was set to 5 s, taking into consideration the longitudinal relaxation time of the
protons [31]. The signals were assigned by comparing their chemical shift and multiplicity with the
Human Metabolome Database and Chenomx software data bank (Chenomx Inc., Edmonton, AB,
Canada, ver 8.1) [32].
The 1H-NMR spectra were pre-processed for quantitative analysis following a method already
described in literature [30]. Briefly, the spectra were baseline-adjusted by means of simultaneous peak
detection and a baseline correction algorithm (SPDBC) implemented in the baseline R package [33].
The spectra were corrected for errors in chemical shift misalignments using an in-house modified
version of Correlation Optimized Shifting (i-Coshift) [34].
2.10. Statistical Data Analysis
The data were analyzed using a Student’s t-test and one-way analysis of variance (ANOVA),
followed by a Tukey post hoc comparison test (SPSS program version 13.0; SPSS Inc., Chicago, IL, USA).
Differences of at least p ≤ 0.05 were considered significant. Iron concentration underwent statistical
analysis in R computational language. In each group, data were considered as probable outliers when
they exceeded by 1.5 times the 0.25–0.75 percentile range. Metabolomics data were analyzed in R,
with sparse principal component analysis (sPCA) performed using a mixOmics package, applying the
sparsity principle as detailed by Shen and Huang [35].
3. Results and Discussion
3.1. Experimental Bread
Three types of experimental bread were prepared, using conventional yeast fermentation:
microencapsulated iron fortified bread (FeMB), ferrous sulphate fortified bread (FeSB), and control
bread (CB) without any iron supplementation. The formula of the FeSB was based on that of
FeMB, but instead of microencapsulated iron an equivalent amount of modified starch, ascorbic acid,
and ferrous sulphate was used, in the form of individual compounds. The content of iron in the
fortified breads was 21 mg Fe 100 g−1·WM (Wet Mass), ten times higher than that in the control bread.
To meet WHO recommendations for cereal flour fortification, ferrous sulphate was selected as the iron
source [36]. The presence of ferrous ions in the final experimental breads was determined, as ferrous
ions are easily oxidized to ferric ions, especially under the conditions used in the baking process
(high temperature and humidity), which may accelerate the reaction. The presence of Fe(II) in the
experimental breads was confirmed in a reaction with Ferene S. During the trial period, the daily iron
intake of each piglet was 21 mg. This dose complies with experimental findings and recommendations.
According to the National Research Council’s current guidelines, neonatal pigs require 7 to 16 mg of
iron per day for normal growth [37]. Table 3 presents the composition of the experimental breads.
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Table 3. Component analysis of breads administered to the pigs. All values are given in respect to
the fresh bread mass. (FeMB: bread with microencapsulated iron; FeSB: bread with free iron; CB:
control bread).
Sample/Breads FeMB FeSB CB
Humidity (g 100 g−1) 38.90 ± 0.83 38.11 ± 0.19 41.27 ± 0.77
Proteins (g 100 g−1) 7.62 ± 0.53 8.10 ± 0.57 7.55 ± 0.53
Fat (g 100 g−1) 1.76 ± 0.20 1.43 ± 0.05 1.78 ± 0.42
Carbohydrates
Total (g 100 g−1) 45.59 46.56 44.01
Soluble (Sucrose/Saccharose) (g 100 g−1) 1.35 1.00 0.69
Insoluble (fiber) (g 100 g−1) 1.61 1.61 1.61
Ash (g 100 g−1) 1.71 ± 0.04 1.73 ± 0.04 1.62 ± 0.05
NaCl (g 100 g−1) 1.47 1.47 1.47
Total Fe (mg 100 g−1) 21.10 ± 0.82 21.20 ± 0.63 2.80 ± 0.20
3.2. Body Weight and Blood Analyses
The body weights of the piglets and their main blood parameters are reported in Table 4.
Table 4. Effect of bread administration on growth performance and blood parameters. Value are
means ± SD. Means with different superscripts differ p < 0.05. Capital superscripts represent
differences within the same group between P44 and P51. Lowercase superscript represent differences
between the groups at the same experimental time. (BW: body weight; HCT: hematocrit; Hb:
hemoglobin; RBC: red blood cells; WBC: white blood cells; RET: reticulocytes; GGT: gamma
glutamyltransferase; TIBC: total iron binding capacity; UIBC: unsaturated iron binding capacity;
TSAT: TIBC saturation percentage).
Intramuscular Iron Supplementation
Piglets Group
FeMB-G1 FeSB-G2 CB-G3 CB-G4
no no no yes
Body weight (kg) P44 6.9 ± 1.33
a 7.2 ± 1.5 a 7,6 ± 1.0 a 10.5 ± 1.5 b
P51 6.8 ± 1.1 a 6.3 ± 1.4 a 7.0 ± 1.6 a 10.5 ± 1.9 b
Hb (g/dL) P44 6.1 ± 2.0 aA 6.0 ± 2.5 aA 5.3 ± 1.5
a 8.8 ± 1.7 b
P51 7.2 ± 2.2 abB 8.0 ± 2.5 abB 6.3 ± 2.4 a 9.3 ± 1.7 b
HCT (%) P44 21.7 ± 5.6
a 21.1 ± 6.5 aA 20.2 ± 4.8 a 29.7 ± 3.6 b
P51 23.5 ± 5.5 ab 25.5 ± 6.7 abB 21.7 ± 5.9 a 29.1 ± 4.1 b
RBC (106/mm3)
P44 5.10 ± 0.9 a 4.59 ± 1.18 aA 5.26 ± 1.68 a 7.37 ± 0.86 b
P51 5.8 ± 0.9 a 5.60 ± 1.12 aB 5.78 ± 1.70 a 7.27 ± 0.40 b
WBC (103/mm3)
P44 14.3 ± 2.2 11.5 ± 3.4 11.5 ± 1.6 17.5 ± 4.1
P51 10.3 ± 3 8.1 ± 3.9 8.2 ± 2.5 14.1 ± 4.6
RET (103/mm3)
P44 415.5 ± 189.2 634.1 ± 171.7 503.3 ± 64.5 299.1 ± 93.7
P51 86.6 ± 57.9 112.4 ± 48.9 95.8 ± 28.5 58.6 ± 18.3
Glucose (mg/dL) P44 107.3 ± 17.2 104.5 ± 9 112.5 ± 15.7 104 ± 7.3
P51 162.2 ± 33.2 136.3 ± 26.9 150.8 ± 52.1 145.7 ± 27.3
GGT (U/L) P44 32.5 ± 5.2 30.1 ± 3.5 28.3 ± 5.3 36.9 ± 4.2P51 38.4 ± 8.1 37.3 ± 8.3 29.3 ± 4.4 36.8 ± 5.5
Iron (serum) (µg/dL) P44 97.2 ± 81.5 83.8 ± 59.1 41.8 ± 30.6 85 ± 47.2
P51 66.3 ± 54.1 69.7 ± 47.8 39.8 ± 44 88.5 ± 42.5
TIBC (µg/dL) P44 507 ± 51 528.5 ± 79.1 532.5 ± 118.9 455.7 ± 38.1
P51 402.8 ± 53.5 412.5 ± 60.2 388.3 ± 59.6 399 ± 60.4
UIBC (µg/dL) P44 409.8 ± 75.3 444.7 ± 117 490.8 ± 144.1 370.7 ± 76.2
P51 336.5 ± 84.9 342.8 ± 99.7 348.5 ± 91.8 310.5 ± 101
Iron (whole blood) (mg/L) P51 229.7 ± 64.2 a 253.2 ± 65.8 ab 215.7 ± 63.1 a 284.3 ± 49.2 b
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Parameters showing statistical differences and their correlations are reported in the upper part
of the table. All piglets were of similar weight on day 5 (data not shown) and analysis showed that
all of the animals enrolled in the study were healthy. The group that received IM iron supplements
subsequently gained significantly more weight than those which did not receive the experimental
diet. This might be explained by the fact that animals that received the IM supplementation at 5 days,
had more time (from P5 to P44) to restore and correct anemia and balance all of the physiological
gastrointestinal mechanisms. Their weight is indeed significantly higher since the beginning of the
trial P44. Over the week of the trial, the differences were maintained between the live body weights of
the piglets in the positive control group (CB-G4) and those of the piglets in all other groups.
Episodes of diarrhea were reported from the second day of the experimental diet. However,
none of the four groups showed a higher incidence of diarrhea than the others. Thomaz et al. [38]
report that animals fed diets supplemented with trace minerals in inorganic form suffer higher rates of
diarrhea than animals fed diets without mineral supplements. However, this was not confirmed in the
present study.
Levels of variables such as hematocrit (HCT), hemoglobin (Hb), and red blood cells (RBC) seem to
have been influenced by the kind of bread administered (Table 4). Groups that received iron fortified
breads (FeMB-G1; FeSB-G2) showed significant increases in these parameters (p≤ 0.05) as compared to
piglets fed with the control bread (CB-G3 and CB-G4). At the beginning of the experiment, the FeSB-G2
group was classified as anemic, whereas after the treatment they showed only borderline anemia [39].
The impact of iron microencapsulation on Hb was not as marked as that of unencapsulated ferrous
sulfate, although there was no significant difference between the treatments (p > 0.05).
No changes in levels of leukocytes were observed in any of the groups over the course of the
experiment. Clinical chemistry analyses did not reveal significant variations at different times or
between groups, proving that the animals were healthy. CB-G4 showed the highest concentrations of
Gamma-glutamyl transferase (GGT) at P44. By the end of the trial, GGT had increased in the groups fed
with iron fortified breads (FeMB-G1 and FeSB-G2), reaching or exceeding the level observed previously
for CB-G4, while it remained stable in group CB-G3 (the lowest noted concentration). Therefore,
this parameter seems to be directly related to iron supplementation, since it increased after both IM
and oral administration. In all of the groups, the glucose concentration in the blood was higher on
day 51 than on day 44. This is related to the fact that the animals were fed 1 hour before euthanasia in
order to collect gastric content. The iron content in serum varied widely between animals. Despite this
large individual variation, it can be noted that the iron levels in orally supplemented groups (FeMB-G1
and FeSB-G2) decreased, while they remained stable in groups fed with control bread (CB-G3 and
CB-G4). Our hypothesis is that the increase in nutritional iron availability may stimulate iron storage
or tissue-binding mechanisms, therefore lowering the UIBC (Unsaturated Iron Binding Capacity) and
TIBC (Total Iron Binding Capacity). TSAT (TIBC Saturation Percentage) appears to have remained
stable, with minimal variations.
CB-G4 did not show large differences for the main indices of hematopoiesis and anemia.
The probable reason is that the diet used (LISD) was designed to have a low iron content. Whereas,
a normal farm practice is IM supplementation and the use of specific iron-rich diets.
Overall, all of the blood parameters fell within the physiological reference intervals available
in the literature for piglets. Therefore, despite some differences between the groups at P44 and P51,
the trial did not determine any dangerous or important alterations in the animals, which remained
healthy throughout the trial [40].
3.3. Relative Expression of HAMP, IREG1, and DMT1
The effects of the different bread types on mRNA of hepcidin (HAMP) in the liver, and on IREG1
and DMT1 at the duodenal level, did not differ in a statistically significant manner (Figure 1). Moreover,
the gene expression of HAMP calculated with reference to CB-G4 shows a progressively decreasing
trend, starting from the group of anemic piglets fed bread with microencapsulated iron (FeMB-G1),
Nutrients 2017, 9, 272 9 of 15
followed by the group given non-encapsulated iron bread FeSB-G2 and finally the anemic group,
CB-G3, which was fed with control bread (Figure 1A). This trend, showing a slight up-regulation
in groups with iron fortified bread in respect to the anemic group, can be explained by the fact that
iron is the most important proven biological factor for inducing hepcidin expression, while there
is also evidence that both iron saturation of plasma and hepatic iron loading stimulate hepcidin
synthesis [25,29].
The relative gene expression of IREG1 (Figure 1B) and DMT1 (Figure 1C) in relation to the group
with encapsulated iron supplementation (CB-G4) showed a relatively higher value for piglets in
FeSB-G2. The increasing trend in intestinal DMT1 mRNA (Figure 1C) for piglets fed with FeMB-G1
and FeSB-G2 is likely due to the animals’ anemic status and increased need for dietary Fe to meet
erythropoietic demands. The increasing trend in IREG1 expression observed for animals fed with
FeMB-G1 and FeSB-G2 as compared with CB-G4 corresponds to the opposite trend observed for
HAMP expression. Hepcidin binds to IREG1, causing internalization and degradation of the protein
and decreasing cellular Fe export [7,41].
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3.4. Ferritin Determination
Although ferritin is mainly found as a cytosolic protein, small amounts of ferritin are secreted
into serum, in amounts closely reflecting the size of the body’s iron stores [42,43]. Plasmatic ferritin
can be used to identify differences within the physiological range, reflecting non-heme iron levels in
the liver and spleen more than other blood values [44].
The effects of consuming the different types of bread on the piglets’ plasmatic levels of ferritin are
presented in Figure 2. There were no statistically significant differences between the groups in terms of
the amounts of ferritin detected in the plasma samples using a specific ELISA kit, although the group
fed with FeMB-G1 had the highest ferritin levels. This lack of significant differences may be due to the












































Figure 2. Effect of consuming different breads on plasmatic levels of ferritin in piglets.
3.5. Iron Absorption and Storage
The total iron content in the intestinal mucosa and internal organs after 51 days of life is
shown in Table 5. The iron content in the intestines of the animals which did not receive iron
supplementation was 18.4 ± . · e·kg−1. This was significantly lower (p < 0.05) than in CB-G4.
In t, the iron content in the in estinal muc sa of the animals that rec ved either oral or IM
iron supplementation ranged from 25.0 to 28.0 (mg/kg·WM), and did not diff r from the CB-G4
group (p > 0.05). Iron cont nt in the intestinal mucosa is known to be controlle tightly by d uble
regulation [3]. The first regulatory mechanism controls the passage of iro into intestinal mucosal
absorptive cells (enterocytes). Iron transfer from the basal surface into the blood is then regulated
according to the body’s needs at the time. Excess iron entering the mucosal cells can be incorporated
into ferritin, stored in the intestinal cells for 2–3 days, and finally lost by exfoliation and apoptosis of
the cell [37]. The iron levels of the piglets fed with iron fortified breads were close to iron adequate
status. This suggests that iron absorbed from lumen was not stored in the epithelial cell, but uptaken
by transferrin and transported systemically to the body.
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Table 5. Effects of dietary iron supplementation in the form of iron fortified bread and intramuscular
injection on iron concentration (mg·kg−1·WM) in organs of post-weanling piglets. Values are expressed
as means ± SD; Values in the same row with different superscripts differ significantly p < 0.05 (n = 6).
Samples
Piglets Group
FeMB-G1 FeSB-G2 CB-G3 CB-G4
Intestinal mucosa P51 25.0 ± 8.1 a 28.0 ± 11.5 a 18.4 ± 4.6 b 27.2 ± 4.4 a
Liver P51 29.0 ± 7.6 b 30.3 ± 10.1 b 20.0 ± 6.9 c 56.2 ± 24.7 a
Heart P51 33.0 ± 9.9 b 35.4 ± 8.1 b 26.3 ± 8.4 c 46.0 ± 12.4 a
Spleen P51 9.4 ± 2.0 ab 10.1 ± 1.2 ab 8.3 ± 1.6 b 10.5 ± 2.4 a
kidney P51 28.2 ± 8.6 ab 27.3 ± 8.0 ab 24.5 ± 7.3 b 33.0 ± 8.6 a
Feces
P44 130.4 ± 39.7 a 84.2 ± 17.2 a 98.2 ± 31.3 a 119.9 ± 27.3 a
P51 324.4 ± 129.5 b 168.8 ± 83.7 ab 58.5 ± 18.5 a 139.2 ± 92.4 a
Oral supplementation with iron in FeMB or FeSB forms resulted in a statistically significant
increase in the iron content of the liver, by up to 51.6% and 53.9%, respectively, with respect to the
CB-G3 group. The concentration of Fe showed a clear tendency to increase in orally supplemented
groups compared to CB-G3, confirming the positive effect of this Fe source on absorption and storage
in the body.
To understand the extent to which oral supplementation moved iron content away from
typical levels for anemic non-supplemented piglets, we calculated the differences shown by each
supplemented piglet from those of the piglets in groups CB-G3 and CB-G4. We then set up a paired
comparison between the distances, using Welch’s t-test. [45] The supplemented piglets, independent of
the kind of supplementation, showed an intermediate iron content in relation to the CB-G3 and CB-G4
groups in each of the studied body organs with the exception of liver, where the iron content was
closer to that of CB-G3.
Piglets given increased daily iron intake in the form of FeMB-1 or FeSB-2 showed significantly
higher iron content in their hearts in comparison with CB-G3 (p < 0.05), but did not reach the level
observed in piglets given IM supplementation from day 5 of life. In both orally supplemented
groups, iron accumulation in the heart and liver, the organs most commonly affected by iron overload,
remained below the values observed in CB-G4. At the end of the intervention trial, there were no
statistical differences in terms of iron content in the spleens of supplemented animals, where iron
content reached similar levels of around 10 mg·g−1. The iron content in the spleens of animals not
given supplementation was lower, although the increase caused by one week of oral supplementation
was not statistically significant.
A comparison of the iron content in feces from individual animals showed a broad range of
variation. In the feces of the FeMB-1 group, iron content varied from 94 to 180 mg/kg on 44 day and
from 282 to 485 mg/kg on day 51. However, with increased iron intake there was an up to twofold
increase in excretion. At the same time, in the CB-G3 iron excretion decreased by half.
Pigs fed with FeSO4 or microencapsulated FeSO4 had higher iron concentrations in the heart, liver,
and intestinal mucosa compared with iron-deficient pigs, indicating that iron supplementation was
effective at improving the iron status of the tested organs. These results are in agreement with those
obtained by Fang et al., [46] who observed that 10 days of supplementation in the form of ferrous sulfate
or iron glycine chelate increased iron content in the heart, liver, and lungs of iron-deficient piglets.
3.6. Fecal Metabolome
To provide an overview of the changes that occurred over the course of the experiment in the
intestinal environments of piglets in different test groups, the metabolome of feces collected at the
beginning and at the end of the experiment was investigated by means of high-resolution proton
magnetic resonance spectroscopy (1H-NMR) and multivariate analysis. In several related studies,
these methods have been found optimal for following the possible consequences of inflammation
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caused by exogenous agents [47–49]. Sixty-six molecules were quantified, mainly pertaining
to amino acids, short chain fatty acids and organic acids. Fifteen other signals were detected,
pertaining to different unknown molecules. The underlying structure of the data was represented in
a multidimensional space using principal component analysis (Figure 3). The score plot highlighted
the differences between the samples, while the loading plot provided a visual representation of the
most important molecules that determined those differences. Along the first principal component
(PC1), accounting for 23.5% of the total variance, the samples collected at P44 are grouped around
negative values, while the samples collected at P51 are grouped around positive values. The linear
combination of the molecules giving rise to PC1 therefore provides a superbly concise representation
of the growth of the animals. Piglets belonging to group CB-G4 appear at P44 with less negative values
than the others, which are closer to CB-G4 animals at P51, as a one tail Wilcox test confirmed. This was
not unexpected, as such piglets were anticipated to be characterized by a more balanced physiological
condition than those in any other group, with positive consequences for the overall development of
the animals. The relative position of samples collected at P51 is remarkably different from the position
of samples obtained at P44, as revealed by an ANOVA test. In fact, the CB-G4 samples are flanked
by FeMB-G1, which has the highest PC1 values, by FeSB-G2 with intermediate values, and by CB-G3
which has the lowest values.
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Figure 3. Score l t ( ) of a PCA analysis of fecal metabolome. To facilitate the visualization
of the differences of the samples at P51, their scores along PC1 are summarized by boxplots (C);
Corresponding loading plot (B), in which only the 10 most important variables, as calculated by sPCA,
are reported. The 81 loadings are also summarized by the molecular group in panel (D). In panels
(C,D), different lowercase letters indicate statistically different groups (p < 0.05). (G1, G2, G3, G4 refer
respectively to the groups fed with: microencapsulated iron bread (FeMB-G1); bread containing the
same quantity of iron sulphate; starch and citric acid (FeSB-G2); control bread (CB-G3), and control
bread with IM iron supplements at P5 (CB-G4)).
A recent work on human subjects showed that s me iron replaceme t ther pies ay cause
inflam ation accompanied by dra c modifica ion f gut microbiota and metabolome [50].
Prompted by these findings, we investigated the intra-group distances of the piglet at P44 and
P51, by considering the Euclidean space cons ituted by the concentration of all the mol cules studied
by NMR, scaled to unit variance. FeSB treatment caused a si nificant (p < 0.05) increase in the
variability of the metabolome, with the average distance between FeSB-G2 piglets increasing by
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175% after iron supplementation. This trend was confirmed when the samples were observed
in the principal component space shown in Figure 3, or in the space of intermediate complexity.
In contrast, groups FeMB-G1, CB-G3, and CB-G4 showed no statistical differences between P44 and
P51, suggesting that iron supplementation through microcapsules had a milder effect on gut microbiota
and metabolome than did fortification with iron sulphate.
The loading plot of the PCA model reveals that the metabolic cycles mostly responsible for the
highlighted trends involved the production of amino acids and decarboxylation. In fact, amino acids
appear significantly more concentrated in samples located around positive PC1 values, while molecules
belonging to the chemical group of amines appear more concentrated in samples with negative
PC1 values.
4. Conclusions
This study has shown that bread fortified with ferrous sulphate or encapsulated ferrous sulphate
provided effective treatment of anemia in piglets. Indeed, after a relatively short treatment time
(7 days), animals initially classified as anemic, due to lack of exogenous iron supplementation,
showed noticeable signs of improvement regarding hematological indicators of anemia. Fortified bread
could therefore also provide a source of bioavailable iron for humans, which should be of interest to the
functional foods industry. However, little difference was observed during the seven-day intervention
trial between using microencapsulated iron or the same amount of ferrous sulphate. It might be
expected that over the course of a longer study iron microencapsulation could obviate the negative
effects of free iron supplementation, and this should be the focus of further research.
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